Glycation as an atherogenic modification of LDL

Current Opinion in Lipidology

Volumn 19, Issue 4, 2008, Pages 378-384

  Younis, Nahla ^a   Sharma, Reena ^b   Soran, Handrean ^b   Charlton Menys, Valentine ^b   Elseweidy, Mohamed ^a   Durrington, Paul N ^b  

^a Zagazig University   (Egypt)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cardiovascular disease; Glycation of LDL; Oxidation of LDL; Small dense LDL

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; GLUCOSE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KAEMPFEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LYSINE; MORIN; MYRICETIN; QUERCETIN; RUTOSIDE; SCAVENGER RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; DIABETES MELLITUS; GLYCATION; HUMAN; MACROPHAGE; OXIDATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN TRANSPORT; REVIEW; ATHEROSCLEROSIS; GLYCOSYLATION; KINETICS; METABOLISM; OXIDATION REDUCTION REACTION;

ATHEROSCLEROSIS; CHOLESTEROL, LDL; GLYCOSYLATION; HUMANS; KINETICS; OXIDATION-REDUCTION;

EID: 53149109790     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328306a057     Document Type: Review

References (85)

1. Bunn HF, Higgins PJ. Reaction of monosaccharides with proteins: possible evolutionary significance. Science 1981; 213:222-224.
2. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344:109-116.
3. Voziyan PA, Khalifah RG, Thibaudeau C, et al. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J Biol Chem 2003; 278:46616-46624.
4. Brown BE, Mahroof FM, Cook NL, et al. Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins. Diabetologia 2006; 49:775-783.
5. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63:582-592.
6. Hernebring M, Brolen G, Aguilaniu H, et al. Elimination of damaged proteins during differentiation of embryonic stem cells. Proc Natl Acad Sci U S A 2006; 103:7700-7705.
7. McLellan AC, Phillips SA, Thornalley PJ. The assay of methylglyoxal in biological systems by derivatization with 1, 2-diamino-4,5-dimethoxybenzene. Anal Biochem 1992; 206:17-23.
8. Peppa M, He C, Hattori M, et al. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 2003; 52:1441-1448.
9. Koenig RJ, Peterson CM, Kilo C, et al. Hemoglobin AIcas an indicator of the degree of glucose intolerance in diabetes. Diabetes 1976; 25:230-232.
10. Dolhofer R, Wieland OH. Increased glycosylation of serum albumin in diabetes mellitus. Diabetes 1980; 29:417-422.
11. Pu LJ, Lu L, Shen WF, et al. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J 2007; 71:1067-1073.
12. + levels in NIDDM. J Diabetes Complications 2002; 16:359-362.
13. Tames FJ, Mackness MI, Arrol S, et al. Nonenzymatic glycation of apolipo-protein B in the sera of diabetic and nondiabetic subjects. Atherosclerosis 1992; 93:237-244.
14. Ryle C, Donaghy M. Nonenzymatic glycation of peripheral nerve proteins in human diabetics. J Neurol Sci 1995; 129:62-68.
15. Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91:2463-2469.
16. Lyons TJ, Bailie KE, Dyer DG, et al. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 1991; 87:1910-1915.
17. McDermott AM, Xiao TL, Kern TS, Murphy CJ. Nonenzymatic glycation in corneas from normal and diabetic donors and its effects on epithelial cell attachment in vitro. Optometry 2003; 74:443-452.
18. Kaji Y, Usui T, Oshika T, et al. Advanced glycation end products in diabetic corneas. Invest Ophthalmol Vis Sci 2000; 41:362-368.
19. Monnier VM, Cerami A. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 1981; 211:491-493.
20. Garlick RL, Mazer JS, Chylack LT Jr, et al. Nonenzymatic glycation of human lens crystalline. Effect of aging and diabetes mellitus. J Clin Invest 1984; 74:1742-1749.
21. Acosta J, Hettinga J, Fluckiger R, et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A 2000; 97:5450-5455.
22. Verzijl N, DeGroot J, Oldehinkel E, et al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 2000; 350:381-387.
23. Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001; 888:256-262.
24. Hein G, Weiss C, Lehmann G, et al. Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis 2006; 65:101-104.
25. Assimakopoulos D, Danielides V, Kontogianis N, et al. Sudden hearing loss as the presenting symptom of diabetes mellitus. Diabetes Res Clin Pract 2001; 53:201-203.
26. Howes KA, Liu Y, Dunaief JL, et al. Receptor for advanced glycation end products and age-related macular degeneration. Invest Ophthalmol Vis Sci 2004; 45:3713-3720.
27. Gebhardt C, Riehl A, Durchdewald M, et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008; 205:275-285.
28. Allmen EU, Koch M, Fritz G, Legler DF. V domain of RAGE interacts with AGEs on prostate carcinoma cells. Prostate 2008; 68:748-758.
29. Steinbrecher UP, Witztum JL. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984; 33:130-134.
30. Knott HM, Brown BE, Davies MJ, Dean RT. Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modified and oxidized particles. Eur J Biochem 2003; 270: 3572-3582.
31. Brown BE, Dean RT, Davies MJ. Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells. Diabetologia 2005; 48:361-369.
32. Schleicher E, Deufel T, Wieland OH. Nonenzymatic glycosylation of human serum lipoproteins. Elevated epsilon-lysine glycosylated low density lipoprotein in diabetic patients. FEBS Lett 1981; 129:1-4.
33. Sanguinetti SM, Schreier LE, Elbert A, et al. Detection of structural alterations in LDL isolated from type 2 diabetic patients: application of the fructosamine assay to evaluate the extent of LDL glycation. Atherosclerosis 1999; 143:213-215.
34. Cohen MP, Lautenslager G, Shea E. Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur J Clin Chem Clin Biochem 1993; 31:707-713.
35. Akanji AO, Abdella N, Mojiminiyi OA. Determinants of glycated LDL levels in nondiabetic and diabetic hyperlipidaemic patients in Kuwait. Clin Chim Acta 2002; 317:171-176.
36. Cohen MP, Jin Y, Lautenslager GT. Increased plasma glycated low-density lipoprotein concentrations in diabetes: a marker of atherogenic risk. Diabetes Technol Ther 2004; 6:348-356.
37. Kobayashi K, Ogasahara N, Sakoguchi T, et al. Correlation between glycated lipoproteins and fructosamine level in serum. Chem Pharm Bull (Tokyo) 1991; 39:2149-2151.
38. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46:733-749.
39. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27:1496-1504.
40. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996; 7:167-171.
41. Chait A, Brazg R, Tribble D, Krauss R. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94:350-356.
42. Younis N, Charlton-Menys V, Sharma R, et al. Glycation of LDL in nonpeople: small dense LDL is preferentially glycated both In vivo and in vitro. Atherosclerosis (in press) (2008), doi:10.1016/j.atherosclerosis.2008. 04.036. This is the first report that small dense LDL is preferentially glycated in people without diabetes and that it has greater susceptibility to undergo glycation when compared with other LDL subclasses in vitro.
43. Nakamura K, Nakazawa Y, Ienaga K. Acid-stable fluorescent advanced glycation end products: vesperlysines A, B, and C are formed as crosslinked products in the Maillard reaction between lysine or proteins with glucose. Biochem Biophys Res Commun 1997; 232:227-230.
44. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991; 266:11654-11660.
45. Noble RP. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 1968; 9:693-700.
46. Sobal G, Menzel J, Sinzinger H. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study. Prostaglandins Leukot Essent Fatty Acids 2000; 63:177-186.
47. Rashid I, van Reyk DM, Davies MJ. Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. FEBS Lett 2007; 581:1067-1070.
48. Habeeb AF. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem 1966; 14:328-336.
49. Duell PB, Oram JF, Bierman EL. Nonenzymatic glycosylation of HDL resulting in inhibition of high-affinity binding to cultured human fibroblasts. Diabetes 1990; 39:1257-1263.
50. Posch K, Simecek S, Wascher TC, et al. Glycated low-density lipoprotein attenuates shear stress-induced nitric oxide synthesis by inhibition of shear stress-activated L-arginine uptake in endothelial cells. Diabetes 1999; 48:1331-1337.
51. Zimmermann R, Panzenbock U, Wintersperger A, et al. Lipoprotein lipase mediates the uptake of glycated LDL in fibroblasts, endothelial cells, and macrophages. Diabetes 2001; 50:1643-1653.
52. Jack CM, Sheridan B, Kennedy L, Stout RW. Nonenzymatic glycosylation of low-density lipoprotein. Results of an affinity chromatography method. Diabetologia 1988; 31:126-127.
53. Gambino R, Uberti B, Alemanno N, et al. In vivo oxidizability of LDL in type2 diabetic patients in good and poor glycemic control. Atherosclerosis 2004; 173:103-107.
54. Kortlandt W, Benschop C, Erkelens DW, Thijssen JH. A simple method for the measurement of total and glycated apolipoprotein B and its relevance to apolipoprotein-B metabolism in diabetes mellitus. Clin Chim Acta 1989; 186:109-117.
55. Panteghini M, Bonora R, Pagani F. Determination of glycated apolipoprotein B in serum by a combination of affinity chromatography and immunonephelometry. Ann Clin Biochem 1994; 31:544-549.
56. Li D, Devaraj S, Fuller C, et al. Effect of alpha-tocopherol on LDL oxidation and glycation: in vitro and In vivo studies. J Lipid Res 1996; 37:1978-1986.
57. Huang CN, Horng JS, Yin MC. Antioxidative and antiglycative effects of six organosulfur compounds in low-density lipoprotein and plasma. J Agric Food Chem 2004; 52:3674-3678.
58. Jenkins AJ, Thorpe SR, Alderson NL, et al. In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetes. Metabolism 2004; 53:969-976.
59. Shea EA, Cohen MP. Immunologic detection and measurement of glycated apolipoprotein B with site specific monoclonal antibodies. J Immunol Methods 1993; 162:85-95.
60. Zhang J, Ren S, Sun D, Shen GX. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18:1140-1148.
61. Kobayashi K, Watanabe J, Umeda F, Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J 1995; 42:461-465.
62. Menzel EJ, Sobal G, Staudinger A. The role of oxidative stress in the long-term glycation of LDL. Biofactors 1997; 6:111-124.
63. Imanaga Y, Sakata N, Takebayashi S, et al. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis 2000; 150:343-355.
64. Bucala R, Makita Z, Koschinsky T, et al. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 1993; 90:6434-6438.
65. Holvoet P, Vanhaecke J, Janssens S, et al. Oxidised LDL and malondialde-hyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998; 98:1487-1494.
66. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidised low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003; 41:360-370.
67. Tsimikas S, Witztum JL. Measuring circulating oxidised low-density lipoprotein to evaluate coronary risk. Circulation 2001; 103:1930-1932.
68. Kesaniemi YA, Witztum JL, Steinbrecher UP. Receptor-mediated catabolism of low density lipoprotein in man. Quantitation using glucosylated low density lipoprotein. J Clin Invest 1983; 71:950-959.
69. 14C]sucrose-labelled low-density lipoprotein in vivo. Biochem J 1984; 224:21-27.
70. Witztum JL, Mahoney EM, Branks MJ, et al. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes 1982; 31:283-291.
71. Lopes-Virella MF, Sherer GK, Lees AM, et al. Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type 1 (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia 1982; 22:430-436.
72. Steinbrecher UP, Witztum JL, Kesaniemi YA, Elam RL. Comparison of glucosylated low density lipoprotein with methylated or cyclohexanedione-treated low density lipoprotein in the measurement of receptor-independent low density lipoprotein catabolism. J Clin Invest 1983; 71:960-964.
73. Sobal G, Sinzinger H, Menzel EJ. Binding of long-term glycated low density lipoprotein and AGE-albumin by peripheral monocytes and endothelial cells. J Recept Signal Transduct Res 1999; 19:267-281.
74. Wang X, Bucala R, Milne R. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proc Natl Acad Sci U S A 1998; 95:7643-7647.
75. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84:489-497.
76. Brown BE, Rashid I, van Reyk DM, Davies MJ. Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages. FEBS J 2007; 274:1530-1541. This study confirms the more powerful effect of aldehydes compared with glucose on LDL modification as tested by the change in particle charge, aggregation and amino acid modification. It also confirms the time-dependent accumulation of cholesteryl esters and apoB100 particles in primary human monocyte-derived macrophages via scavenger receptors (SR-A and CD36).
77. Lam MC, Tan KC, Lam KS. Glycoxidized low-density lipoprotein regulates the expression of scavenger receptors in THP-1 macrophages. Atherosclerosis 2004; 177:313-320.
78. Nivoit P, Wiernsperger N, Moulin P, et al. Effect of glycated LDL on micro-vascular tone in mice: a comparative study with LDL modified in vitro or isolated from diabetic patients. Diabetologia 2003; 46:1550-1558.
79. Witztum JL, Steinbrecher UP, Fisher M, Kesaniemi A. Nonenzymatic glucosylation of homologous low density lipoprotein and albumin renders them immunogenic in the guinea pig. Proc Natl Acad Sci U S A 1983; 80:2757-2761.
80. Lee YT, Hsu CC, Lin MH, et al. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur J Pharmacol 2005; 513:145-150.
81. Odani H, Shinzato T, Matsumoto Y, et al. Increase in three alpha, betadicarbonyl compound levels in human uremic plasma: specific In vivo determination of intermediates in advanced Maillard reaction. Biochem Biophys Res Commun 1999; 256:89-93.
82. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417:750-754.
83. Ou CC, Tsao SM, Lin MC, Yin MC. Protective action on human LDL against oxidation and glycation by four organosulfur compounds derived from garlic. Lipids 2003; 38:219-224.
84. Ghaffari MA, Mojab S. Influence of flavonols as in vitro on low density lipoprotein glycation. Iran Biomed J 2007; 11:185-191.
85. Boldyrev AA, Severin SE. The histidine-containing dipeptides, carnosine and anserine: distribution, properties and biological significance. Adv Enzyme Regul 1990; 30:175-194.